polymorphonuclear cells drive lung injury in Mycoplasma pneumoniae pneumonia
CD177+ PMNs facilitate the development and progression of MPP. Both SNAI2 and CD177 may serve as potential therapeutic targets, whereas CD177 and IL-17 could function as prognostic biomarkers for the clinical management of SMPP and refractory MPP.